$ Value
—
Shares
25,000
Price
—
Filed
Apr 17
Insider
Name
Felix Lourdes
Title
—
CIK
0001569735
Roles
Transaction Details
Transaction Date
2026-04-15
Code
A
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
25,000
Footnotes
On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant. | The canceled Options provided for vesting 50% on the grant date, the remaining 50% vesting in equal installments of 12.5% on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested.
Filing Info
Felix Lourdes's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-15 | LIXT | A | — |
| 2026-04-15 | LIXT | D | — |
| 2025-12-24 | LIXT | A | $0 |
| 2025-08-11 | LRHC | A | $0 |
Other Insiders at LIXT (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| Felix Lourdes | — | — | 2026-04-15 |
|
Pursglove Geordan Garrett
CEO and Chairman of the Board
|
— | — | 2026-04-15 |
| Sawyer Jason David | — | — | 2026-04-15 |
| Holloway Michael Andrew | — | — | 2026-04-15 |
|
Stazzone Peter
Chief Financial Officer
|
— | — | 2026-04-15 |
| Primus Guy Warren | — | — | 2026-04-15 |